Rajesh Gandhi of Massachusetts General Hospital, Boston and colleagues in the AIDS Clinical Trial Group ACTG tested HIV patients to know if elevated immune activation is driven by the low levels of HIV is present in patients undergoing treatment.
They used blood samples of people who took part in ACTG clinical trials, measured molecular markers of HIV, immune system activation and inflammation in 101 people before and during antiretroviral drugs treatment for 7 years.
Researchers discovered connection between HIV levels, immune activation and inflammation in HIV patients
The link does not continue during treatment, this shows that elevated immune activation during treatment is not driven by HIV in the blood.
People with higher HIV levels before treatment may have higher HIV levels during treatment.
No comments:
Post a Comment